Sorafenib, a multi-tyrosine kinase inhibitor, is a standard treatment for advanced
hepatocellular carcinoma (HCC). The present study was undertaken to determine whether …

Sorafenib has been systemically utilized to therapy the advanced hepatocellular carcinoma
(HCC). Natural killer cells (NKs) are important cytotoxic innate lymphocytes, which can exert …

Sorafenib, FDA-approved therapy for patients with advanced hepatocellular carcinoma
(HCC), leads to limited improvement in overall survival. However, it may indirectly impact the …

Antiangiogenic and cytotoxic effects are considered the principal mechanisms of action of
sorafenib, a multitarget kinase inhibitor approved for the treatment of hepatocellular …

Dysfunction of natural killer (NK) cells is associated with poor prognosis in hepatocellular
carcinoma (HCC). We explored the phenotypic and functional characteristics of peripheral …

Hepatocellular carcinoma (HCC) is the most frequent malignancy of the liver, which is
considered the fourth leading cause of cancer-related death in the United States. Liver …

Alternatively polarized macrophages (Mϕ) shape the microenvironment of hepatocellular
carcinoma (HCC) and temper anticancer immune responses. We investigated if sorafenib …

Sorafenib, a multikinase inhibitor with antiangiogenic activity, is an approved therapy for
hepatocellular carcinoma (HCC). It is unclear whether the proinflammatory and …

Viral infection of the liver is a major risk factor for hepatocellular carcinoma (HCC). Natural
killer (NK) cells recognize virally infected and oncogenically transformed cells, suggesting a …

Natural Killer (NK) cells are effector lymphocytes involved in tumor immunosurveillance,
however, the specific mechanism in hepatocellular carcinoma (HCC) has not been well …